S&P 500   4,604.79 (+0.83%)
DOW   34,657.07 (+0.50%)
QQQ   395.28 (+0.37%)
AAPL   168.63 (+2.01%)
MSFT   335.56 (+1.50%)
FB   316.87 (-2.34%)
GOOGL   2,872.24 (+1.21%)
AMZN   3,498.17 (-0.25%)
TSLA   1,139.70 (-0.44%)
NVDA   322.30 (-1.36%)
BABA   124.76 (-2.17%)
NIO   39.58 (+1.15%)
CGC   10.34 (-3.45%)
AMD   153.92 (-2.81%)
GE   95.21 (+0.23%)
MU   87.36 (+4.00%)
T   22.55 (-1.23%)
F   19.92 (+3.80%)
DIS   144.79 (-0.08%)
PFE   54.52 (+1.47%)
ACB   6.25 (-2.65%)
AMC   32.25 (-4.98%)
BA   193.97 (-1.96%)
S&P 500   4,604.79 (+0.83%)
DOW   34,657.07 (+0.50%)
QQQ   395.28 (+0.37%)
AAPL   168.63 (+2.01%)
MSFT   335.56 (+1.50%)
FB   316.87 (-2.34%)
GOOGL   2,872.24 (+1.21%)
AMZN   3,498.17 (-0.25%)
TSLA   1,139.70 (-0.44%)
NVDA   322.30 (-1.36%)
BABA   124.76 (-2.17%)
NIO   39.58 (+1.15%)
CGC   10.34 (-3.45%)
AMD   153.92 (-2.81%)
GE   95.21 (+0.23%)
MU   87.36 (+4.00%)
T   22.55 (-1.23%)
F   19.92 (+3.80%)
DIS   144.79 (-0.08%)
PFE   54.52 (+1.47%)
ACB   6.25 (-2.65%)
AMC   32.25 (-4.98%)
BA   193.97 (-1.96%)
S&P 500   4,604.79 (+0.83%)
DOW   34,657.07 (+0.50%)
QQQ   395.28 (+0.37%)
AAPL   168.63 (+2.01%)
MSFT   335.56 (+1.50%)
FB   316.87 (-2.34%)
GOOGL   2,872.24 (+1.21%)
AMZN   3,498.17 (-0.25%)
TSLA   1,139.70 (-0.44%)
NVDA   322.30 (-1.36%)
BABA   124.76 (-2.17%)
NIO   39.58 (+1.15%)
CGC   10.34 (-3.45%)
AMD   153.92 (-2.81%)
GE   95.21 (+0.23%)
MU   87.36 (+4.00%)
T   22.55 (-1.23%)
F   19.92 (+3.80%)
DIS   144.79 (-0.08%)
PFE   54.52 (+1.47%)
ACB   6.25 (-2.65%)
AMC   32.25 (-4.98%)
BA   193.97 (-1.96%)
S&P 500   4,604.79 (+0.83%)
DOW   34,657.07 (+0.50%)
QQQ   395.28 (+0.37%)
AAPL   168.63 (+2.01%)
MSFT   335.56 (+1.50%)
FB   316.87 (-2.34%)
GOOGL   2,872.24 (+1.21%)
AMZN   3,498.17 (-0.25%)
TSLA   1,139.70 (-0.44%)
NVDA   322.30 (-1.36%)
BABA   124.76 (-2.17%)
NIO   39.58 (+1.15%)
CGC   10.34 (-3.45%)
AMD   153.92 (-2.81%)
GE   95.21 (+0.23%)
MU   87.36 (+4.00%)
T   22.55 (-1.23%)
F   19.92 (+3.80%)
DIS   144.79 (-0.08%)
PFE   54.52 (+1.47%)
ACB   6.25 (-2.65%)
AMC   32.25 (-4.98%)
BA   193.97 (-1.96%)
NASDAQ:MYGN

Myriad Genetics Earnings Date, Estimates, & History

$25.92
+0.06 (+0.23%)
(As of 12/1/2021 01:15 PM ET)
Add
Compare
Today's Range
$25.88
▼
$26.65
50-Day Range
$25.86
▼
$34.76
52-Week Range
$17.18
▼
$36.95
Volume
13,928 shs
Average Volume
600,015 shs
Market Capitalization
$2.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.51

Earnings Summary

Upcoming
Earnings Date
Feb. 22
Estimated

Actual EPS
(Nov. 2)
-$0.02

Consensus EPS
(Nov. 2)
-$0.02

Last Year's Q4 EPS
(11/9/2020)
-$0.15

Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

Myriad Genetics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Myriad Genetics Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Myriad Genetics (NASDAQ:MYGN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20212$0.01$0.09$0.05 
Q2 20213($0.24)($0.17)($0.20) 
Q3 20213($0.23)($0.07)($0.15) 
Q4 20213($0.11)$0.00($0.06) 
FY 202111($0.57)($0.15)($0.35)
Q1 20221($0.07)($0.07)($0.07) 
Q3 20221($0.05)($0.05)($0.05) 
Q4 20221($0.03)($0.03)($0.03) 

MYGN Earnings Information

Myriad Genetics last announced its earnings data on November 2nd, 2021. The reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). The company earned $167.30 million during the quarter, compared to analysts' expectations of $164.35 million. Myriad Genetics has generated ($0.87) earnings per share over the last year (($0.87) diluted earnings per share). Earnings for Myriad Genetics are expected to grow in the coming year, from ($0.45) to ($0.25) per share. Myriad Genetics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 22nd, 2022 based off prior year's report dates.

Myriad Genetics (NASDAQ:MYGN) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
2/22/2022
(Estimated)		        
11/2/20219/30/2021($0.02)($0.02)($0.54)$164.35 million$167.30 million    
8/3/20216/30/2021($0.09)$0.12+$0.21$0.12$163.09 million$189.40 million  
5/2/20213/31/2021($0.15)($0.06)+$0.09$0.20$155.36 million$173.10 million  
2/22/2021Q1 21($0.12)($0.12)$0.21$148.11 million$154.60 million  
11/9/20209/30/2020($0.30)($0.15)+$0.15($0.18)$134.59 million$145.20 million  
8/13/20206/30/2020($0.47)($0.31)+$0.16$0.08$95.44 million$93.20 million  
5/5/20203/31/2020$0.02($0.08)($0.10)$1.23$167.38 million$164.00 million  
2/6/2020Q2 2020$0.22$0.23+$0.01$0.41$209.61 million$195.10 million  
11/4/2019Q1$0.26$0.08($0.18)$0.22$202.34 million$186.30 million  
8/13/2019Q4 19$0.40$0.41+$0.01$0.66$221.64 million$215.40 million  
5/7/20193/31/2019$0.38$0.34($0.04)$0.59$217.76 million$216.60 million
2/5/201912/31/2018$0.34$0.38+$0.04$0.57$217.69 million$216.80 million  
11/6/20189/30/2018$0.30$0.43+$0.13$0.71$203.20 million$202.30 million  
8/21/20186/30/2018$0.33$0.38+$0.05$0.58$195.93 million$200.90 million
5/8/2018Q3$0.27$0.31+$0.04$0.46$188.22 million$193.50 million
2/6/2018Q2 2018$0.2360$0.31+$0.0740$0.17$188.72 million$194.00 million  
11/7/2017Q1 2018$0.21$0.26+$0.05($0.63)$183.52 million$190.20 million
8/8/2017Q4 17$0.26$0.30+$0.04$0.41$193.71 million$200.50 million  
5/2/2017Q3 2017$0.2380$0.27+$0.0320$0.48$188.89 million$196.90 million  
2/7/2017Q2 2017$0.24$0.26+$0.02$0.43$189.72 million$196.50 million  
11/1/2016Q117$0.26$0.23($0.03)$0.48$172.31 million$177.50 million
8/9/2016Q416$0.38$0.36($0.02)$0.40$187.95 million$186.50 million
5/3/2016Q316$0.38$0.41+$0.03$0.38$185.08 million$190.50 million
2/2/2016Q216$0.41$0.45+$0.04$0.49$189.99 million$193.30 million
11/3/2015Q116$0.35$0.41+$0.06$0.45$177.89 million$183.50 million
8/11/2015Q415$0.42$0.41($0.01)$0.56$187.81 million$189.90 million  
5/5/2015Q315$0.39$0.40+$0.01$0.51$183.30 million$180.00 million  
2/3/2015Q215$0.35$0.40+$0.05$0.48$183.41 million$184.40 million  
11/4/2014Q115$0.33$0.25($0.08)$0.29$175.00 million$168.84 million  
8/12/2014Q414$0.46$0.48+$0.02$0.53$187.68 million$188.80 million  
5/6/2014Q314$0.45$0.60+$0.15$0.72$175.23 million$182.92 million  
2/4/2014Q2 2014$0.47$0.66+$0.19$0.66$176.02 million$204.06 million  
11/5/2013Q1 2014$0.46$0.68+$0.22$0.68$167.64 million$202.50 million  
8/13/2013Q4 2013$0.44$0.53+$0.09$0.53$159.87 million$174.10 million  
5/7/2013Q3 2013$0.39$0.46+$0.07$0.46$148.25 million$156.40 million
2/5/2013Q2 2013$0.38$0.42+$0.04$143.71 million$140.70 million  
11/5/2012Q113$0.32$0.36+$0.04$129.84 million$133.40 million
8/14/2012$0.34$0.34  
5/1/2012$0.32$0.34+$0.02  
1/31/2012$0.31$0.33+$0.02
11/1/2011$0.27$0.29+$0.02
8/9/2011$0.29$0.30+$0.01  
5/3/2011$0.25$0.31+$0.06
1/27/2011$0.26$0.26
11/2/2010Q1 2011$0.23$0.24+$0.01$0.24
8/10/2010Q4 2010$0.33$0.39+$0.06$0.24
5/4/2010Q3 2010$0.38$0.33($0.05)$0.33
2/2/2010Q2 2010$0.34$0.36+$0.02$0.36
11/3/2009Q1 2010$0.32$0.31($0.01)$0.31
8/25/2009Q4 2009$0.23$0.37+$0.14$0.50
5/4/2009Q3 2009$0.23$0.25+$0.02$0.25
2/3/2009Q2 2009$0.17$0.22+$0.05$0.22
11/4/2008Q1 2009$0.07$0.15+$0.08$0.15
8/19/2008Q4 2008($0.12)$0.70+$0.82$0.70
5/6/2008Q3 2008($0.05)($0.05)($0.05)
2/5/2008Q2 2008($0.08)($0.06)+$0.02($0.06)
(Earnings results data provided by Zacks Investment Research)












Myriad Genetics (NASDAQ:MYGN) Earnings Frequently Asked Questions

When is Myriad Genetics's earnings date?

Myriad Genetics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 22nd, 2022 based off last year's report dates. Learn more on MYGN's earnings history

Did Myriad Genetics beat their earnings estimates last quarter?

In the previous quarter, Myriad Genetics (NASDAQ:MYGN) reported ($0.02) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.02). Learn more on MYGN's earnings details

How can I listen to Myriad Genetics's earnings conference call?

The conference call for Myriad Genetics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Myriad Genetics's conference call transcript?

The conference call transcript for Myriad Genetics's latest earnings report can be read online. Read Transcript

How much revenue does Myriad Genetics generate each year?

Myriad Genetics (NASDAQ:MYGN) has a recorded annual revenue of $638.60 million.

How much profit does Myriad Genetics generate each year?

Myriad Genetics (NASDAQ:MYGN) has a recorded net income of -$44.20 million. MYGN has generated -$0.87 earnings per share over the last four quarters.

What is Myriad Genetics's EPS forecast for next year?

Myriad Genetics's earnings are expected to grow from ($0.45) per share to ($0.25) per share in the next year.

This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.